|
Apr 11
|
3 Value Stocks in the Doghouse
|
|
Apr 10
|
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
|
|
Apr 10
|
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
|
|
Mar 15
|
Why Bristol-Myers Squibb Company (BMY) Went Down On Friday?
|
|
Mar 14
|
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
|
|
Mar 14
|
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
|
|
Mar 14
|
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
|
|
Mar 13
|
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
|
|
Mar 13
|
Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?
|
|
Mar 13
|
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
|
|
Mar 12
|
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds?
|
|
Mar 11
|
BMS to acquire longtime cell therapy partner 2seventy bio for $286m
|
|
Mar 11
|
TSVT Up on Acquisition Agreement With BMY for $286 Million
|
|
Mar 11
|
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
|
|
Mar 10
|
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
|
|
Mar 10
|
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?
|
|
Mar 10
|
Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now
|
|
Mar 10
|
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
|
|
Mar 10
|
EC approves BMS’ Opdivo and Yervoy combo for HCC
|
|
Feb 28
|
Drug Stocks Are the New Safe Bet in a Shaky Market
|